| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | VEGFR2 (KDR) |
| Clinical data | |
| Trade names | Cyramza |
| Other names | LY3009806, IMC-1121B |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a614026 |
| License data |
|
| Routes of administration | Intravenous infusion |
| Drug class | Antineoplastic agents |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Metabolism | Probably proteases |
| Elimination half-life | 14 days |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6374H9864N1692O1996S46 |
| Molar mass | 143609.63 g·mol−1 |
  (what is this?) (verify) | |
Ramucirumab([5]), sold under the brand name Cyramza, is a fully human monoclonal antibody (IgG1) used for the treatment of cancer.[3][4] Ramucirumab is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist.[3][4] Ramucirumab was developed by ImClone Systems.[not verified in body] It was isolated from a native phage display library from Dyax.[not verified in body]
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2015". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 10 April 2023.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
- ^ a b c "Cyramza- ramucirumab solution". DailyMed. 27 November 2023. Retrieved 22 October 2024.
- ^ a b c "Cyramza EPAR". European Medicines Agency (EMA). 19 December 2014. Retrieved 22 October 2024.
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ramucirumab, American Medical Association